Kolexia
Voog Eric Oncologie médicale
Voog Eric
Oncologie médicale
Gcs Medecine Nucleaire Sarthe_et Siege
Le Mans, France
118 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Tumeurs de la prostate Myélome multiple Tumeurs prostatiques résistantes à la castration Néphrocarcinome Tumeurs de la vessie urinaire Carcinome transitionnel Métastase tumorale Tumeurs à plasmocytes

Collaborateurs

Voir plus
Denis Fabrice
Denis Fabrice
Gcs Medecine Nucleaire Sarthe_et Siege, Le Mans, France
Facon Thierry
Facon Thierry
Hôpital Huriez, Lille, France
Moreau Philippe
Moreau Philippe
Hôpital Hôtel-Dieu Nantes, Nantes, France
Karlin Lionel
Karlin Lionel
Hôpital Lyon Sud, Pierre-Bénite, France

Industries

Voir plus
Ipsen
10 collaboration(s)
Dernière en 2023
Pfizer
10 collaboration(s)
Dernière en 2023
Merck-Serono
4 collaboration(s)
Dernière en 2023
MSD
2 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer: A Phase 2, Randomized, Open-Label, Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
Essai Clinique (MacroGenics)   18 mars 2024
TALAPRO-2: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Essai Clinique (Pfizer)   15 février 2024
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley): A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination With Other AntiTumor Agents as a Maintenance Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress With First Line Platinum-Containing Chemotherapy (JAVELIN Bladder Medley)
Essai Clinique (Emd Serono)   05 février 2024
Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.
Nature medicine   31 janvier 2024
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.
Nature medicine   04 décembre 2023
Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial.
JAMA oncology   26 octobre 2023
2379P AVENANCE: Subgroup analysis of patients (pts) with advanced urothelial carcinoma (aUC) with histological variants from a real-world (RW) study of avelumab first-line maintenance (1LM)
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
1812P Exploration of germline (g) vs somatic (s) origin of homologous recombination repair (HRR) gene alterations and potential associations with antitumor activity in the HRR-deficient population from TALAPRO-2
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
1807P Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Subgroup analyses of the all-comers cohort from TALAPRO-2 by homologous recombination repair (HRR) status
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
1808P Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel every 2 weeks (16 mg/m2) versus every 3 weeks (25 mg/m2) in the CABASTY phase III trial
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023